We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Ultra-Rapid AST System Provides Critical Results for Sepsis Patients

By LabMedica International staff writers
Posted on 27 Dec 2024
Print article
Image: The QuickMIC system (Photo courtesy of Gradientech)
Image: The QuickMIC system (Photo courtesy of Gradientech)

Sepsis is a critical condition and one of the leading causes of death in hospitals. Millions of adults are diagnosed with sepsis each year, and it is also a primary reason for hospital readmissions. Hospital staff are urged to start treatment for life-threatening sepsis within one hour of diagnosis, often referred to as the 'golden hour.' Now, an ultra-rapid antimicrobial susceptibility testing (AST) system can support the timely and effective management of sepsis, enabling clinicians to make faster decisions regarding antibiotic treatments.

The QuickMIC ultra-rapid AST system, developed by Gradientech AB (Uppsala, Sweden), is designed to provide critical results for sepsis patients. This instrument can analyze a single positive blood culture sample per run, delivering precise minimum inhibitory concentration (MIC) values within 2–4 hours directly from positive blood cultures. The system employs unique technology based on a continuous linear antibiotic gradient, offering greater resolution, precision, and accuracy compared to methods that rely on discrete antibiotic concentrations. Microcolonies of bacteria exposed to this gradient are monitored in real-time using live imaging. The QuickMIC Analyst software then examines the growth patterns along the antibiotic gradient to determine accurate MIC values.

QuickMIC cassettes test each blood culture sample against a panel of multiple antibiotics, with each pre-filled cassette containing twelve antibiotics specifically designed for common sepsis-causing bacteria. The gram-negative antibiotic panel targets pathogens such as E. coli, Klebsiella spp., P. aeruginosa, E. cloacae, A. baumannii, Proteus spp., Citrobacter spp., and S. marcescens. Laboratories can use QuickMIC in conjunction with their preferred rapid identification methods to provide quicker results to clinical teams. Up to twelve QuickMIC instruments can be stacked together, allowing labs to increase testing capacity while saving valuable bench space. QuickMIC and its gram-negative panel are CE-marked and commercially available in Europe, although they are not yet available for sale in the United States.

Related Links:
Gradientech AB

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
H.pylori Test
Humasis H.pylori Card
New
Vaginitis Test
Allplex Vaginitis Screening Assay

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.